>
Switch to:

ORIC Pharmaceuticals Current Ratio

: 26.75 (As of Jun. 2021)
View and export this data going back to 2020. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. ORIC Pharmaceuticals's current ratio for the quarter that ended in Jun. 2021 was 26.75.

ORIC Pharmaceuticals has a current ratio of 26.75. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for ORIC Pharmaceuticals's Current Ratio or its related term are showing as below:

NAS:ORIC' s Current Ratio Range Over the Past 10 Years
Min: 16.78   Med: 27.02   Max: 36.49
Current: 26.75

16.78
36.49

During the past 3 years, ORIC Pharmaceuticals's highest Current Ratio was 36.49. The lowest was 16.78. And the median was 27.02.

NAS:ORIC's Current Ratio is ranked higher than
67% of the 317 Companies
in the Biotechnology industry.

( Industry Median: 4.36 vs. NAS:ORIC: 26.75 )

ORIC Pharmaceuticals Current Ratio Historical Data

The historical data trend for ORIC Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20
Current Ratio
16.84 16.81 32.96

ORIC Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.48 27.29 32.96 36.49 26.75

Competitive Comparison

For the Biotechnology subindustry, ORIC Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

ORIC Pharmaceuticals Current Ratio Distribution

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's Current Ratio falls into.



ORIC Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

ORIC Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2020

Current Ratio (A: Dec. 2020 )=Total Current Assets (A: Dec. 2020 )/Total Current Liabilities (A: Dec. 2020 )
=296.697/9.002
=32.96

ORIC Pharmaceuticals's Current Ratio for the quarter that ended in Jun. 2021 is calculated as

Current Ratio (Q: Jun. 2021 )=Total Current Assets (Q: Jun. 2021 )/Total Current Liabilities (Q: Jun. 2021 )
=264.952/9.904
=26.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ORIC Pharmaceuticals  (NAS:ORIC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


ORIC Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

ORIC Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533.
Executives
Kunkel Lori Anne director C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Chacko Jacob director, officer: President and CEO C/O IGNYTA, INC. 11095 FLINTKOTE AVE., SUITE D SAN DIEGO CA 92121
Topspin Biotech Fund Ii, L.p. 10 percent owner 3 EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Lg Management, Llc 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Topspin Fund L.p. 10 percent owner THREE EXPRESSWAY PLAZA ROSLYN HEIGHTS NY 11577
Heyman Richard A. director 5871 OBERLIN DRIVE, SUITE 150 SAN DIEGO CA 92121
Scheller Richard H director C/O GENENTECH INC 1 DNA WAY MS 49 SOUTH SAN FRANCISCO CA 94080-4990
Guthart Leo 10 percent owner C/O APTUR GROUP INC 475 W TERRA COTTA AVE STE E CRYSTAL LAKE IL 60014
Column Group Ii Gp, Lp 10 percent owner, other: General Partner 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Goeddel David V 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Svennilson Peter director, 10 percent owner 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Gordon Carl L director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)